ESC 365 - Role of ivabradine in development of new onset atrial fibrillation in acute coronary syndrome patients

ESC Premium Access

Role of ivabradine in development of new onset atrial fibrillation in acute coronary syndrome patients

Session: Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment

Topic: Drug therapy

Speaker: Doctor A. Almaghraby (Ras al Khaimah, AE)

Event: ESC Congress 2017

Congress Presentation

About the speaker

Doctor Abdallah Almaghraby

Ibrahim bin Hamad Obaidallah Hospital, Ras al Khaimah (United Arab Emirates)

0 follower

4 more presentations in this session

Discussant: Best Posters in new targets in cardiovascular drug assessment

Individual-specific corrected QT interval (QTcI) obtained from ECGs recorded at fixed timepoints versus QTcI derived using a wider range of stable heart rates from 24-hour Holter recordings

Speaker: Doctor R. Turner (Durham, US)

Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

Speaker: Associate Professor S. Skrtic (Molndal, SE)

Lack of low-density lipoprotein cholesterol (LDL-C) goal attainment among high-risk patients using high or moderate intensity statin therapy in Germany

Speaker: Doctor M. Hatz (Munich, DE)

Access the full session

Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment

Speakers: Doctor A. Almaghraby, Doctor R. Turner, Associate Professor S. Skrtic, Doctor M. Hatz

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by